S. Dickerson

发表

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.

P. A. Harris, L. Kuyper, S. Frye, 2001, Journal of medicinal chemistry.

Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor.

Charles Kung, Lee F Kuyper, Kevan M Shokat, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.

K. Lackey, S. Dickerson, Jun Tang, 2013, Bioorganic & medicinal chemistry letters.

Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.

C. Moore, A. Mathis, J. Botyánszki, 2014, Journal of medicinal chemistry.

Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R).

Brian J. Wilson, L. Shewchuk, P. Sabbatini, 2009, Bioorganic & medicinal chemistry letters.

Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations

Gary K. Smith, S. Dickerson, W. Pendergast, 2004, Cancer Chemotherapy and Pharmacology.

Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2.

J. P. Condreay, J. Ulrich, S. A. Thomson, 2010, Bioorganic & medicinal chemistry letters.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

J. Weiel, Liping Wang, F. Tavares, 2009, Bioorganic & medicinal chemistry letters.

Benzoquinazoline Inhibitor of Thymidylate Synthase Biochemical and Cellular Pharmacology of 1843 U 89 , a Novel Updated

Pendergast, Kathleen, J. Humphreys, 2006 .

N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1.

J. P. Condreay, S. A. Thomson, L. T. Schaller, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3.

S. A. Thomson, J. Boucheron, A. Peat, 2006, Bioorganic & medicinal chemistry letters.

Novel GSK-3 Inhibitor with Improved Cellular Activity.

S. A. Thomson, J. Boucheron, A. Peat, 2004 .

Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.

S. A. Thomson, J. Boucheron, A. Peat, 2004, Bioorganic & medicinal chemistry letters.

Novel GSK-3 inhibitors with improved cellular activity.

S. A. Thomson, J. Boucheron, A. Peat, 2004, Bioorganic & medicinal chemistry letters.

Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.

K. Lackey, Hideyuki Sato, S. Dickerson, 2008, Bioorganic & medicinal chemistry letters.

Benzo[f]quinazoline inhibitors of thymidylate synthase: methyleneamino-linked aroylglutamate derivatives.

R. Ferone, S. Dickerson, W. Pendergast, 1994, Journal of medicinal chemistry.

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.

A. Waterson, R. Griffin, K. Hinkle, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

A. Waterson, R. Griffin, D. Uehling, 2009, Bioorganic & medicinal chemistry letters.

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.

A. Waterson, R. Griffin, D. Uehling, 2008, Bioorganic & medicinal chemistry letters.

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related derivatives.

R. Ferone, S. Dickerson, W. Pendergast, 1993, Journal of medicinal chemistry.

A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity.

S. Frye, R. Hunter, R. Crosby, 2001, Anti-cancer drug design.

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Krystal J Alligood, Karen Lackey, K. Lackey, 2004, Cancer Research.

Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones.

R. Ferone, J. Humphreys, J. Kelly, 1993, Journal of medicinal chemistry.

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Edgar R. Wood, Robert J. Griffin, Michael J. Reno, 2008, Proceedings of the National Academy of Sciences.

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

T. Gilmer, J. Greger, S. Laquerre, 2012, Molecular Cancer Therapeutics.

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.

K. Lackey, R. Mook, A. Walker, 2006, Bioorganic & medicinal chemistry letters.

A Stereooontrolled Approach to Tri and Tetrasubstttuted Cyclohexanones

C. K. Biggers, S. Dickerson, R. J. Chambers, 1989 .

Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.

R. Ferone, J. Humphreys, Gary K. Smith, 1993, Cancer research.

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.

J. Weiel, Liping Wang, F. Tavares, 2009, Bioorganic & medicinal chemistry letters.

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.

Alastair J. King, Alex G. Waterson, A. Waterson, 2013, ACS medicinal chemistry letters.

Preclinical Development Combinations of BRAF , MEK , and PI 3 K / mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK 2118436 Dabrafenib , Mediated by NRAS or MEK Mutations

T. Gilmer, J. Greger, S. Laquerre, 2012 .

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

D. Vanderwall, L. Shewchuk, A. Goetz, 2009, Bioorganic & medicinal chemistry letters.

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.

R. Griffin, F. Tavares, S. A. Thomson, 2004, Journal of medicinal chemistry.

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.

B G Benson, A M Hassell, P. A. Harris, 2001, Science.

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.

A. Waterson, O. Rossanese, A. King, 2011, Bioorganic & medicinal chemistry letters.

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.

R. Hamatake, W. Kazmierski, R. Crosby, 2014, Journal of medicinal chemistry.